Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions
- PMID: 30378175
- PMCID: PMC6460915
- DOI: 10.1002/mc.22937
Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions
Abstract
Wnt pathway activation maintains the cancer stem cell (CSC) phenotype and promotes tumor progression, making it an attractive target for anti-cancer therapy. Wnt signaling at the tumor and tumor microenvironment (TME) front have not been investigated in depth in head and neck squamous cell carcinoma (HNSCC). In a cohort of 48 HNSCCs, increased Wnt signaling, including Wnt genes (AXIN2, LGR6, WISP1) and stem cell factors (RET, SOX5, KIT), were associated with a more advanced clinical stage. Key Wnt pathway proteins were most abundant at the cancer epithelial-stromal boundary. To investigate these observations, we generated three pairs of cancer-cancer associated fibroblast (CAF) cell lines derived from the same HNSCC patients. 3D co-culture of cancer spheres and CAFs mimicked these in vivo interactions, and using these we observed increased expression of Wnt genes (eg, WNT3A, WNT7A, WNT16) in both compartments. Of these Wnt ligands, we found Wnt3a, and less consistently Wnt16, activated Wnt signaling in both cancer cells and CAFs. Wnt activation increased CSC characteristics like sphere formation and invasiveness, which was further regulated by the presence of CAFs. Time lapse microscopy also revealed preferential Wnt activation of cancer cells. Wnt inhibitors, OMP-18R5 and OMP-54F28, significantly reduced growth of HNSCC patient-derived xenografts and suppressed Wnt activation at the tumor epithelial-stromal boundary. Taken together, our findings suggest that Wnt signaling is initiated in cancer cells which then activate CAFs, and in turn perpetuate a paracrine signaling loop. This suggests that targeting Wnt signaling in the TME is essential.
Keywords: Sox2; Wnt signaling; Wnt3a; cancer stem cells; head and neck squamous cell cancer.
© 2018 Wiley Periodicals, Inc.
Conflict of interest statement
Disclosures
The authors declare no conflict of interest and have no relevant disclosures.
Figures
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65(1):5–29. - PubMed
-
- Clevers H Wnt/beta-catenin signaling in development and disease. Cell 2006;127(3):469–480. - PubMed
-
- Niehrs C The complex world of WNT receptor signalling. Nature reviews Molecular cell biology 2012;13(12):767–779. - PubMed
Publication types
MeSH terms
Grants and funding
- RC1 DE020649/DE/NIDCR NIH HHS/United States
- R21DE019712/NH/NIH HHS/United States
- Peter and Rhonda Grant Foundation/International
- R21 DE019712/DE/NIDCR NIH HHS/United States
- R01 DE024371/DE/NIDCR NIH HHS/United States
- R01 CA213102/CA/NCI NIH HHS/United States
- T32DC012280/NH/NIH HHS/United States
- P30 AR057212/AR/NIAMS NIH HHS/United States
- P30-CA046934/NH/NIH HHS/United States
- R01CA149456/NH/NIH HHS/United States
- Daniel and Janet Mordecai Foundation/International
- DE020649/NH/NIH HHS/United States
- T32CA17468/NH/NIH HHS/United States
- P30 CA046934/CA/NCI NIH HHS/United States
- P30-AR057212/NH/NIH HHS/United States
- T32 DC012280/DC/NIDCD NIH HHS/United States
- T32 CA174648/CA/NCI NIH HHS/United States
- R01DE024371/NH/NIH HHS/United States
- R01 CA149456/CA/NCI NIH HHS/United States
